# Nasogastric Tube Market

> Nasogastric Tube Market Research Report By Application (Nutritional Support, Medication Administration, Gastric Decompression), By Material Type (Polyvinyl Chloride, Silicone, Rubber), By End User (Hospitals, Home Care Settings, Long-term Care Facilities), By Tube Size (Small Bore, Large Bore) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 4.89%
- **2025:** USD 559.6 Million
- **2035:** USD 902.0 Million
- **Key Players:** Cardinal Health, Avanos Medical, B. Braun, Fresenius Kabi, Medline Industries, Vygon, Cook Medical, Teleflex

**Report ID:** MRFR/HC/32180-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Nidhi Mandole · **Last Updated:** November 07, 2026

**URL:** https://www.marketresearchfuture.com/reports/nasogastric-tube-market-34019

---

## Market Summary

## Nasogastric Tube Market Summary

The global Nasogastric Tube Market was valued at USD 559.6 Million in 2025 and is forecast to reach USD 586.9 Million in 2026, rising to USD 902.0 Million by 2035 at a CAGR of 4.89%. Demand rests on a plain clinical reality: an older, more surgically treated population needs short-term gastric access more often. Two catalysts sharpen the curve. The World Stroke Organization counts more than 12 million new strokes every year, a large share of which leave patients with unsafe swallowing [1], and the NHS patient safety alert on tube misplacement turned objective position checks into standard practice across UK hospitals [2].

Product design is changing faster than at any point in the past two decades. Basic PVC Levin tubes, placed blind and checked by aspirate testing, are giving ground to polyurethane and silicone tubes, ENFit-compatible connectors built to ISO 80369-3 [8], and placement systems that use electromagnetic tracking or pH sensing. Regulation is the main accelerant: EU MDR Annex I requires manufacturers to justify any carcinogenic or endocrine-disrupting phthalate above 0.1% weight by weight [10], which steers hospital procurement away from DEHP-plasticized PVC.

North America holds the leading position with a 38.6% share of 2025 revenue, supported by high ICU bed density and early adoption of guided placement. Asia-Pacific is the fastest-growing region at a 6.2% CAGR, driven by hospital construction in China and India and rapid ageing in Japan. Europe ranks second at USD 153.3 Million, where material rules and silicone preferences for long-dwell placements shape purchasing. Over the next decade, value growth in the Nasogastric Tube Market will come more from specialty designs and home-based care than from raw unit volume.

## Key Report Takeaways

### • By Product Type

- Levin Tubes held a 42.4% share of the Nasogastric Tube Market in 2025, anchored by low unit cost and routine use in acute decompression
- Other Specialty Tubes are forecast to expand at a 6.9% CAGR as hospitals adopt electromagnetic and pH-guided placement
- Salem-Sump Tubes generated USD 205.9 Million in 2025, reflecting dual-lumen demand in upper-GI and bariatric surgery

### • By Technology

- Polyurethane accounted for 40.3% of 2025 demand, favored for short-dwell emergency and surgical placements
- Silicone is projected to post a 7.6% CAGR as long-duration placements shift toward inert, softer materials

### • By Indication

- Dysphagia & Swallowing Disorders represented 48.6% of 2025 revenue, driven by stroke and neurodegenerative disease
- Drug & Nutrient Administration is the fastest-growing indication in the Nasogastric Tube Market at a 9.4% CAGR, supported by oncology nutrition protocols

### • By End User

- Hospitals captured 65.0% of 2025 revenue, reflecting the concentration of placements in ICUs and surgical wards
- Home Healthcare is set to grow at a 7.9% CAGR as enteral care moves out of inpatient settings

### • By Region

- North America led with a 38.6% share in 2025
- Asia-Pacific is forecast to grow at a 6.2% CAGR through 2035
- Europe generated USD 153.3 Million in 2025

## Market Size and Forecast (2021–2035)

Estimates for the Nasogastric Tube Market combine procedure-level demand modeling with supply-side validation. Unit volumes were built from hospital admission, surgical, oncology and stroke incidence data, multiplied by average selling prices by product type and material, then cross-checked against manufacturer disclosures, distributor interviews and tender records. The 2022 slowdown reflects inventory normalization after pandemic-era ICU stockpiling, while forecast years assume steady price-mix gains from specialty and silicone tubes alongside moderate volume growth.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising stroke and neurological dysphagia burden | +1.1% | Global | Long-term (≥4 yr) | [1] |
| Placement safety mandates and verification protocols | +0.9% | North America, Europe | Medium-term (2–4 yr) | [2] |
| Expanding gastrointestinal and bariatric surgery | +0.6% | North America, Asia-Pacific | Medium-term (2–4 yr) | [7] |
| Oncology nutrition support | +0.7% | Global | Long-term (≥4 yr) | [6] |
| Migration of enteral care to home settings | +0.8% | North America, Europe | Medium-term (2–4 yr) | [13] |
| Population ageing in Asia-Pacific | +0.6% | Asia-Pacific | Long-term (≥4 yr) | [15] |
| Hospital infrastructure and domestic manufacturing incentives | +0.4% | India, ASEAN, South America | Short-term (≤2 yr) |  |

### Rising Stroke and Neurological Dysphagia Burden

Stroke is the largest single source of tube-dependent dysphagia. The World Stroke Organization reports more than 12 million new strokes annually and over 100 million people living with the after-effects [1]. ASPEN guidance supports early enteral access when oral intake is unsafe [4], and nasogastric placement is the default first-line route in the acute phase because it needs no procedure room or anesthesia. Parkinson's disease, ALS and dementia add a slower but persistent layer of demand in ageing high-income populations.

### Placement Safety Mandates and Verification Protocols

NHS Improvement identified 95 incidents of feeding into the lungs through misplaced tubes between 2011 and 2016 [2], and misplaced tubes remain on the NHS England Never Events list [3]. Hospitals have responded by standardizing tube types, adding pH testing and radiographic confirmation, and piloting electromagnetic guidance. Each step raises value per placement even where unit volumes stay flat, which is why safety policy shapes revenue more than it shapes procedure counts.

### Expanding Gastrointestinal and Bariatric Surgery

The American Society for Metabolic and Bariatric Surgery estimates that roughly 280,000 metabolic and bariatric procedures were performed in the United States in 2022 [7]. Upper-GI, hepatobiliary and colorectal surgery all rely on nasogastric decompression tubes for post-operative gastric emptying, with dual-lumen designs preferred under continuous suction. Enhanced recovery protocols have cut typical dwell time to around 24 hours, but rising surgical throughput keeps aggregate unit demand climbing.

### Oncology Nutrition Support

GLOBOCAN 2022 records more than 900,000 new head and neck cancers worldwide each year [6]. Mucositis during chemoradiation often makes oral feeding impossible for weeks, and many cancer centers now place tubes either prophylactically or at the first sign of weight loss. Esophageal and gastric cancer surgery adds post-operative demand. Together these pathways explain why drug and nutrient delivery is outpacing every other indication.

### Migration of Enteral Care to Home Settings

Payers increasingly prefer to manage stable patients outside acute wards. The ESPEN home enteral nutrition guideline sets out structured criteria for discharging tube-fed patients with nutrition-team follow-up [5], while Medicare reimburses supplies through the annually updated DMEPOS fee schedule [13]. NG tube enteral feeding at home generates recurring replacement demand every few weeks, converting a one-time hospital purchase into a repeat consumable stream for suppliers with home distribution reach.

### Population Ageing in Asia-Pacific

In 2023, 29.1% of people in Japan were 65 years of age or older [15], and by the end of the same year, 297 million people in China were 60 years of age or older [16]. Stroke, aspiration pneumonia, and post-operative nutrition requirements are more common in older patients. Asia-Pacific is at the core of incremental volume growth through 2035 due to the rapid development in long-term care beds in both countries as well as the super-aged transition in South Korea.

### Hospital Infrastructure and Domestic Manufacturing Incentives

India's Production Linked Incentive scheme for medical devices carries a total outlay of INR 3,420 crore , encouraging local production of consumables including feeding and drainage tubes. New district hospitals and private multispecialty chains across India and Southeast Asia are adding ICU beds faster than staff can be trained. Domestic producers supply low-cost PVC and polyurethane tubes into public tenders, expanding access in segments multinationals have historically underserved.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Substitution by gastrostomy for long-term feeding | −0.7% | North America, Europe | Long-term (≥4 yr) | [5] |
| Complications and liability exposure | −0.5% | Global | Medium-term (2–4 yr) | [3] |
| Price pressure from group purchasing and volume-based procurement | −0.6% | United States, China | Short-term (≤2 yr) | [19] |
| EU MDR compliance costs | −0.3% | Europe | Short-term (≤2 yr) | [11] |
| Phthalate and PVC restrictions | −0.3% | Europe | Medium-term (2–4 yr) | [10] |

### Substitution by Gastrostomy for Long-Term Feeding

ESPEN guidance favors percutaneous gastrostomy when enteral feeding is expected to last beyond four to six weeks [5]. As discharge planning improves and endoscopy capacity grows, clinicians move patients from nasal tubes to PEG earlier. That shift trims long-dwell nasogastric volumes in long-term care, where a single gastrostomy can replace several tube changes over a patient's stay.

### Complications and Liability Exposure

Errors that result in feeding into the airway are categorized as Never Events in England, and documented misplacement rates for blind bedside insertion range from 1 to 3% [3]. The clinical burden is increased by sinusitis, nasal ulcers, and patient-initiated removal. Some hospitals restrict insertion to skilled teams because to litigation risk, which slows the number of placements on general wards.

### Price Pressure from Group Purchasing and Volume-Based Procurement

Group purchasing organizations negotiate contracts covering the large majority of US hospitals, and standard Levin tubes are often bundled into broad consumables agreements with minimal margin [19]. In China, provincial volume-based procurement for medical consumables has delivered price cuts frequently above 50%. Commodity tubes face the sharpest compression, pushing suppliers toward premium specialty lines.

### EU MDR Compliance Costs

Regulation (EU) 2023/607 extended MDR transition deadlines to 2027 and 2028 [11], but every legacy tube still needs recertification with fresh clinical and biocompatibility evidence. Notified-body reviews commonly run 13–18 months. Smaller manufacturers with thin margins are rationalizing catalogs rather than recertifying low-volume sizes, reducing choice in some national markets.

### Phthalate and PVC Restrictions

EU MDR requires justification for CMR or endocrine-disrupting phthalates above 0.1% weight by weight [10]. Reformulating PVC with alternative plasticizers raises cost and requires new biocompatibility testing. Price-sensitive buyers in Eastern Europe and emerging markets cannot always absorb the premium for silicone, which slows the value-accretive material transition.

## Opportunities

## Nasogastric Tube Market Opportunities

### Guided Placement Systems for Mid-Tier Hospitals

Due to the high cost of funding, electromagnetic placement platforms have mostly remained in academic institutions. Thousands of community hospitals might be opened by lower-cost consoles, reusable sensor hubs, and per-procedure billing, expanding upon the built foundation of well-established systems [20]. Vendors benefit from a razor-and-blade income model when they combine consoles with exclusive single-use tubes.

### Local Manufacturing in Emerging Markets

India's Scheme for Strengthening the Medical Device Industry, launched with an INR 500 crore outlay in November 2024 , funds common testing facilities and component clusters. Multinationals can license designs or partner with domestic producers to meet price points in India, ASEAN and Brazil. The Nasogastric Tube Market in these regions still runs heavily on imported PVC tubes, leaving room for localized polyurethane production.

### Service-Based and Data-Linked Home Enteral Models

Subscription bundles that include tubes, securement devices, pumps, and clinician check-ins are replacing product sales for home enteral providers [25]. Hospital readmission reporting and payer audits can be supported by placement-confirmation logs and connected-pump usage data, resulting in a data service that vendors can charge for. Early adopters secure switching expenses and recurrent revenue.

### PVC-Free and Silicone Portfolios for Europe

Hospitals preparing for phthalate restrictions want full PVC-free catalogs rather than piecemeal substitutions. Suppliers able to document ISO 10993-1 biocompatibility across the full size range [9] can win multi-year national framework contracts. New silicone resin capacity in China should narrow the cost gap with polyurethane over the forecast period.

### Neonatal and Pediatric Specialty Tubes

Neonatal feeding requires small-bore tubes, precise dosing and minimal mucosal trauma. The ISO 80369-3 enteral connector standard [8], including low-dose tip syringes, has prompted NICUs to replace legacy inventories. Purpose-built neonatal silicone tubes with depth markings and radiopaque stripes command premium pricing and face limited competition.

## Future Outlook

## Nasogastric Tube Market Future Outlook

Four structural themes will shape how the Nasogastric Tube Market evolves through 2035, each shifting value toward safer, longer-lasting and more connected products.

### Sensor-Guided and AI-Assisted Placement

Aspirate pH strips are being replaced by real-time tracking and automated image assessment for placement confirmation. While AI systems trained to identify tube location on chest radiographs are being included into radiology workflows, bedside confirmation is provided by integrated pH sensors and electromagnetic tip tracking. In high-income institutions, guided placement may become the norm for non-emergent insertions by the early 2030s, increasing average selling costs throughout the specialty tier.

### Home and Value-Based Care

Reimbursement models that penalize readmissions favor earlier discharge of tube-fed patients with remote support. ESPEN home nutrition standards [5] and US DMEPOS coverage [13] provide the framework. Suppliers that combine tubes, pumps, training and telehealth follow-up will capture a growing share of revenue, while hospitals increasingly judge vendors on post-discharge outcomes rather than unit price.

### Materials Transition and Sustainability

PVC will lose share steadily as phthalate restrictions [10] and hospital sustainability targets tighten. Silicone and polyurethane must meet ISO 10993-1 biological evaluation requirements [9], and suppliers that publish lifecycle and recyclable-packaging data will gain an edge in European tenders. Expanded silicone resin capacity in Asia should reduce the material premium meaningfully before 2030.

### Demographic Pressure in Asia-Pacific

According to sources, the proportion of people over 65 will climb from 10% in 2022 to 16% by 2050 [14], with Asia-Pacific accounting for the majority of this growth. Over the course of the next ten years, the demand for enteral access will increase more quickly in China, Japan, South Korea, and India than in any other region due to the fact that stroke, aspiration risk, and frailty scale with age.

## Segment Insights

## Nasogastric Tube Market Segmentation

### By Product Type

The Nasogastric Tube Market by product type spans Levin Tubes, Salem-Sump Tubes and Other Specialty Tubes, with value shifting steadily toward feature-rich designs.

| Segment | Key Metric (2025 Share / 2025 Value / 2026–2035 CAGR) | Primary Demand Driver |
| --- | --- | --- |
| Levin Tubes | 42.4% | Low-cost acute decompression and high-turnover wards |
| Salem-Sump Tubes | USD 205.9 Million | Continuous suction in upper-GI and bariatric surgery |
| Other Specialty Tubes | 6.9% CAGR | Electromagnetic, pH-sensing and dual-function designs |

Levin Tubes lead on volume because single-lumen designs remain the cheapest option for short-term drainage and feeding in emergency departments. Salem-Sump Tubes earn a price premium where continuous suction is required, since the vent lumen prevents mucosal adherence. Other Specialty Tubes, including electromagnetic-tipped, pH-sensing and weighted feeding designs, post the fastest growth as hospitals tie placement policy to objective confirmation.

### By Technology

Material choice in the Nasogastric Tube Market divides into Polyvinyl Chloride, Polyurethane and Silicone, each aligned with a different dwell time and price point.

| Segment | Key Metric (2025 Share / 2025 Value / 2026–2035 CAGR) | Primary Demand Driver |
| --- | --- | --- |
| Polyvinyl Chloride | USD 204.3 Million | Lowest unit cost for very short-term use |
| Polyurethane | 40.3% | Cost-performance balance for short-dwell placements |
| Silicone | 7.6% CAGR | Biocompatibility for long-duration placements |

Polyurethane holds the largest share because it softens at body temperature yet keeps enough stiffness for easy insertion, suiting placements of a few days. Polyvinyl Chloride remains common in cost-constrained settings but faces phthalate restrictions in Europe. Silicone grows fastest, favored for multi-week dwell times where reduced nasal ulceration and patient discomfort justify its higher price.

### By Indication

By indication, the Nasogastric Tube Market covers Dysphagia & Swallowing Disorders, Gastrointestinal Decompression, Drug & Nutrient Administration, and Gastric Lavage & Poisoning.

| Segment | Key Metric (2025 Share / 2025 Value / 2026–2035 CAGR) | Primary Demand Driver |
| --- | --- | --- |
| Dysphagia & Swallowing Disorders | 48.6% | Stroke and neurodegenerative disease |
| Gastrointestinal Decompression | USD 147.7 Million | Post-operative ileus and bowel obstruction |
| Drug & Nutrient Administration | 9.4% CAGR | Oncology nutrition and critical care medication delivery |
| Gastric Lavage & Poisoning | 1.8% CAGR | Residual toxicology use in emergency care |

Dysphagia & Swallowing Disorders dominate as stroke survivors and patients with neurodegenerative disease require weeks of enteral access. Gastrointestinal Decompression tracks surgical volumes, though enhanced recovery protocols shorten dwell times. Drug & Nutrient Administration grows fastest on head and neck oncology protocols and ICU medication delivery, while Gastric Lavage & Poisoning continues a slow decline as toxicology guidance narrows lavage use.

### By End User

End users in the Nasogastric Tube Market include Hospitals, Long-Term Care Facilities, Home Healthcare and Ambulatory Surgical Centers.

| Segment | Key Metric (2025 Share / 2025 Value / 2026–2035 CAGR) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 65.0% | ICU, emergency and surgical placements |
| Long-Term Care Facilities | USD 84.5 Million | Chronic dysphagia in elderly residents |
| Home Healthcare | 7.9% CAGR | Reimbursed discharge of stable tube-fed patients |
| Ambulatory Surgical Centers | 5.8% CAGR | Outpatient bariatric and GI procedures |

Hospitals generate most revenue because nearly all initial placements happen in ICUs, emergency departments and surgical wards. Long-Term Care Facilities hold steady demand, though gastrostomy conversion caps growth. Home Healthcare expands fastest as payers favor earlier discharge with remote nursing support, and Ambulatory Surgical Centers add volume as bariatric and endoscopic procedures move to outpatient settings.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025 Share / 2025 Value / 2026–2035 CAGR) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.6% | Guided placement adoption, home enteral reimbursement, GPO contracting |
| Europe | USD 153.3 Million | Silicone and PVC-free transition, MDR recertification, Never Event compliance |
| Asia-Pacific | 6.2% CAGR | Hospital expansion, ageing populations, local manufacturing |
| South America | 6.2% | Public health system procurement, import substitution |
| Middle East & Africa | USD 26.3 Million | Private hospital build-out, insurance expansion |
| Total | USD 559.6 Million | — |

Regional dynamics in the Nasogastric Tube Market reflect differences in ICU capacity, safety regulation, reimbursement and demographic pressure. North America leads on value, Europe leads on material regulation, and Asia-Pacific leads on growth.

### North America

| Country | Key Metric (Share of Region / 2025 Value / 2026–2035 CAGR) | Key Driver |
| --- | --- | --- |
| US | 84.5% | High ICU density and electromagnetic placement adoption |
| Canada | USD 21.4 Million | Provincial safety standards and long-term care demand |
| Mexico | 5.6% CAGR | IMSS hospital expansion and private surgical growth |

The United States dominates regional revenue on the strength of critical care capacity and early uptake of objective placement confirmation. FDA support for the ENFit connector transition has driven inventory replacement across hospitals and home care , and Medicare coverage of enteral supplies through the DMEPOS fee schedule underpins home demand [13]. Canada's provincial patient safety programs favor standardized tube kits, while Mexico's growth reflects new public hospitals and rising private bariatric volumes.

### Europe

| Country | Key Metric (Share of Region / 2025 Value / 2026–2035 CAGR) | Key Driver |
| --- | --- | --- |
| Germany | 24.8% | DRG-funded surgical volume and early silicone adoption |
| UK | USD 27.9 Million | NHS Never Event compliance and placement audits |
| France | 17.1% | Home hospitalization (HAD) programs |
| Italy | USD 17.6 Million | Ageing population and stroke unit expansion |
| Spain | 4.9% CAGR | Regional health service tenders favoring polyurethane |
| Nordic Countries | 7.3% | PVC-free procurement policies |
| Russia | 3.1% CAGR | Import substitution and domestic production |
| Rest of Europe | USD 15.2 Million | EU funding for hospital modernization in Central Europe |

Germany leads European demand through high surgical throughput and early preference for silicone in long-dwell use. The UK remains the region's most safety-driven market, with Never Event status for misplaced tubes [3] pushing trusts toward pH testing and guided placement. EU MDR phthalate rules [10] shape procurement continent-wide, and the Nordic Countries already run PVC-free tenders. Russia's growth is restrained by import substitution policy that favors domestic suppliers.

### Asia-Pacific

| Country | Key Metric (Share of Region / 2025 Value / 2026–2035 CAGR) | Key Driver |
| --- | --- | --- |
| China | 34.2% | Tertiary hospital build-out and volume-based procurement |
| India | 7.8% CAGR | ICU bed expansion and domestic manufacturing incentives |
| Japan | USD 26.4 Million | Super-aged population and long-term care demand |
| South Korea | 8.1% | Super-aged transition and national insurance coverage |
| ASEAN | 7.1% CAGR | Private hospital chains and medical tourism |
| Rest of Asia-Pacific | USD 10.9 Million | Australian and New Zealand hospital standards |

China accounts for the largest regional share as tertiary hospitals add ICU beds, although volume-based procurement compresses prices on standard tubes. An ageing base of about 297 million people aged 60 and above sustains demand [16]. Japan's 29.1% share of residents aged 65 and over [15] and biennial fee revisions [24] support stable, premium-leaning purchasing. India and ASEAN deliver the fastest growth as private hospital chains expand critical care.

### South America

| Country | Key Metric (Share of Region / 2025 Value / 2026–2035 CAGR) | Key Driver |
| --- | --- | --- |
| Brazil | 52.6% | SUS public procurement and private hospital networks |
| Argentina | USD 7.3 Million | Social security (obras sociales) hospital purchasing |
| Rest of South America | 4.4% CAGR | Colombian and Chilean hospital investment |

Brazil anchors regional demand through the SUS public health system and large private hospital groups, with ANVISA registration acting as the main entry barrier for foreign suppliers. Argentina's purchasing is constrained by currency volatility and import controls, favoring local distributors. Colombia and Chile are investing in private ICU capacity, supporting steady growth in polyurethane tubes.

### Middle East & Africa

| Country | Key Metric (Share of Region / 2025 Value / 2026–2035 CAGR) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | USD 6.8 Million | Vision 2030 health sector privatization |
| UAE | 6.4% CAGR | Private hospital expansion and medical tourism |
| South Africa | 19.4% | Private hospital groups and surgical volume |
| Egypt | 5.3% CAGR | Universal Health Insurance rollout |
| Rest of MEA | USD 6.1 Million | Donor-funded hospital programs |

Saudi Arabia's Vision 2030 health reforms are adding private hospital capacity and standardizing procurement through national purchasing bodies. The UAE grows on private-sector investment and medical tourism, often specifying Western-brand tubes. South Africa's private hospital groups drive most regional surgical demand, while Egypt's phased Universal Health Insurance program is expanding public hospital access province by province.

## Competitive Benchmarking

## Competitive Benchmarking

The Nasogastric Tube Market shows medium concentration. The top five suppliers hold an estimated 48–54% of global revenue, and the Herfindahl-Hirschman Index sits in an estimated 650–800 range, indicating a moderately fragmented field. Multinationals dominate specialty and guided-placement products in high-income markets, while regional manufacturers compete on price in standard PVC and polyurethane tubes across Asia, South America and Africa [19][20][21].

| Company | Est. Revenue Share Range | Key Offerings for Nasogastric Tube Market | Strategic Positioning |
| --- | --- | --- | --- |
| Cardinal Health | ~15–18% | Kangaroo feeding tubes, Salem-sump and Levin tubes | Broad GPO contract coverage and US hospital distribution |
| Avanos Medical | ~9–12% | CORTRAK electromagnetic placement system and feeding tubes | Leader in guided placement technology |
| B. Braun | ~8–11% | Nasogastric feeding tubes, enteral sets and ENFit accessories | Strong European hospital presence |
| Fresenius Kabi | ~7–10% | Freka nasogastric tubes, enteral pumps and nutrition | Integrated nutrition and device bundles |
| Medline Industries | ~6–9% | Salem-sump and Levin tubes, procedure kits | Private-label scale and logistics reach |
| Vygon | ~3–5% | Neonatal and pediatric feeding tubes | Specialist in NICU products |
| Cook Medical | ~3–5% | Specialty nasogastric and nasojejunal tubes | Endoscopy and GI specialty focus |
| Teleflex | ~2–4% | Gastric and airway-adjacent tubing | Critical care portfolio breadth |
| Applied Medical Technology | ~2–4% | Enteral access devices and securement systems | Innovation in tube securement |
| Nestlé Health Science | ~2–3% | Compat enteral feeding tubes and pumps | Nutrition-led home care bundles |
| Romsons | ~1–3% | PVC and polyurethane Ryle's tubes | Low-cost leader in India and export markets |

## Recent News & Developments

## Recent News & Developments

Policy, regulatory and corporate events since 2023 have reshaped supply conditions and procurement in the Nasogastric Tube Market.

- European Commission (March 2023): Regulation (EU) 2023/607 extended MDR transition deadlines to 2027 and 2028, giving tube manufacturers more time to recertify legacy products and averting near-term supply gaps [11]
- Ministry of Health, Labour and Welfare, Japan (April 2024): The FY2024 medical fee revision took effect, adjusting reimbursement for inpatient and home care services that include enteral nutrition management [24]
- Owens & Minor (July 2024): Announced an agreement to acquire home medical equipment provider Rotech Healthcare for about USD 1.36 billion, signaling consolidation in home care supply channels [23]
- Department of Pharmaceuticals, India (November 2024): Launched the Scheme for Strengthening the Medical Device Industry with an INR 500 crore outlay to fund component manufacturing and testing infrastructure
- Teleflex (February 2025): Announced plans to separate into two independent companies, a move that could reshape critical care and surgical product portfolios [22]
- Owens & Minor (June 2025): Terminated the Rotech acquisition after regulatory review, leaving home enteral distribution fragmented [23]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | The Nasogastric Tube Market covers Levin, Salem-sump and specialty tubes made from PVC, polyurethane and silicone, used for feeding, drug delivery, decompression and lavage across hospitals, long-term care, home healthcare and ambulatory surgical centers. |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 559.6 Million |
| Market Size in 2035 | USD 902.0 Million |
| CAGR (2026–2035) | 4.89% |
| Fastest Growing Segments | Drug & Nutrient Administration (9.4% CAGR); Home Healthcare (7.9% CAGR); Silicone (7.6% CAGR); Other Specialty Tubes (6.9% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Cardinal Health, Avanos Medical, B. Braun, Fresenius Kabi, Medline Industries, Vygon, Cook Medical, Teleflex, Applied Medical Technology, Nestlé Health Science, Romsons |
| Valuation Currency | USD Million |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: What should procurement teams check when sourcing products in the Nasogastric Tube Market?**
A: Prioritize ENFit compatibility, full-length radiopaque lines and clear depth markings that support documented placement checks. Limiting each ward to one or two standard SKUs reduces selection errors and simplifies training [4].

**Q: How do Levin and Salem-sump tubes differ in practice?**
A: Levin tubes have a single lumen and suit intermittent drainage or feeding. Salem-sump tubes add a vent lumen that stops suction from grabbing the stomach lining, a safety edge buyers in the Nasogastric Tube Market weigh for continuous suction.

**Q: Can nasogastric tubes be managed safely at home?**
A: Yes, for short-to-medium durations when caregivers are trained in securement and position checks. Suppliers in the Nasogastric Tube Market increasingly bundle teaching materials and telehealth follow-up with home kits [5].

**Q: How does the ENFit transition affect buyers in the Nasogastric Tube Market?**
A: Facilities must switch tubes, syringes, pumps and extension sets together to avoid relying on temporary adapters. Phased ward-by-ward rollouts with dedicated stock counts prevent mixed inventories and connector mismatches [8].

**Q: Are reprocessed nasogastric tubes a viable cost-saving option?**
A: No, these tubes are labeled single-use, and reprocessing raises infection and material-fatigue risks. Savings in the Nasogastric Tube Market come instead from SKU rationalization and multi-year contracts [10].

**Q: What makes a new entrant competitive in the Nasogastric Tube Market?**
A: Parallel clearances in the US, EU and China, plus access to group purchasing contracts, matter most. Sensor features win hospital pilots, but distribution reach determines volume [19].

**Q: How long can a nasogastric tube stay in place?**
A: PVC tubes are usually replaced within about a week, polyurethane lasts several weeks and silicone can remain longer under manufacturer labeling. These dwell limits directly set replacement volumes across the Nasogastric Tube Market [9].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/nasogastric-tube-market-34019*